drugset / Trial / NCT03951142

Imaging Perfusion Restrictions From Extracellular Solid Stress - An Open-label Losartan Study

NCT03951142

Phase 2 Unknown 165 enrolled Kyrre Eeg Emblem
RandomizedParallel-groupOpen-labelDiagnostic

Summary

An open-label, single institutional phase II trial of losartan in patients with primary and metastatic brain tumors with an individual stepped-wedge, randomized, assessor-blinded, dose-finding design on three indications.

Timeline

Start
2019-10-01
Primary completion
2024-10-01
Completion
2024-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Losartan Other / unclassified 25 mg
Subject Losartan Other / unclassified 50 mg
Subject Losartan Other / unclassified 100 mg